Agios Pharmaceuticals (NASDAQ:AGIO) Lowered to Sell at StockNews.com

StockNews.com cut shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a research report sent to investors on Monday.

AGIO has been the topic of several other research reports. JPMorgan Chase & Co. restated a neutral rating and set a $46.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an outperform rating in a report on Tuesday, June 4th. The Goldman Sachs Group boosted their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a neutral rating in a research report on Tuesday, June 4th. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Agios Pharmaceuticals currently has an average rating of Hold and an average price target of $50.67.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $45.23 on Monday. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -7.16 and a beta of 0.77. The firm has a 50 day simple moving average of $37.10 and a 200-day simple moving average of $30.10. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $49.06.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. The business had revenue of $8.19 million for the quarter, compared to the consensus estimate of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The business’s revenue was up 46.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.47) EPS. Equities analysts expect that Agios Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total transaction of $214,642.05. Following the transaction, the director now directly owns 137,396 shares in the company, valued at $3,785,259.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.93% of the stock is owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of large investors have recently bought and sold shares of AGIO. Quest Partners LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter worth $41,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Agios Pharmaceuticals by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 5,040 shares during the period. NEOS Investment Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at about $210,000. Entropy Technologies LP acquired a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $286,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 942 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.